AVEG 006X; VEU 006

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study extended ONLY for subjects who have previously received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover study)

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) March 25, 1991
MN rgp120 Env gp120 B
MN rgp120 Protein
USA 28